Melanotan 2, which is also known as MT-2 or Melanotan II, is a peptide that, through various forms of clinical study and research, has been shown to increase the skin’s protection against damaging ultraviolet, or UV, rays. It is not to be confused with the peptide Melanotan I.
How Melanotan 2 Operates
The peptide Melanotan 2 with the alpha-melanocyte stimulating hormone, which is otherwise referred to as a–MSH. This particular hormone is secreted by the pituitary gland; the pea-sized gland that is located at the base of the brain at the bottom of the hypothalamus. The pituitary gland serves as the main point of the endocrine system, and is oversees the regulation, control, and monitoring of a host of the body’s processes.
Some of these processes include:
Body temperature control and regulation
Water balance through reabsorption
Thyroid gland functionality
Blood pressure regulation
Metabolism regulation (that is, the conversion of food into energy)
Specifically, Melanotan 2 engages the hormones that are produced by the pituitary gland known as melanocortins. These specific hormones are responsible for the regulation and control of hair and skin pigmentation. The secretion that is released is referred to as melanin. The hormones come to activity through the exposure to ultraviolet, or UV, rays; this exposure generates the secretion of melanin, which in turn presents itself on the skin. This process is scientifically referred to as melanogenisis. There are two main effects behind the process of melanogenesis. First, the release of the melanin from melanocortins brings about a darkening of the skin’s pigment. Second, the release works as a natural means of protection, as the process guards against ultraviolet ray exposure. The process, in turn, acts as a safeguard against a host of skin ailments and afflictions that result from the extended exposure ultraviolet rays, including several types of skin cancers.
According to various clinical studies, the half-life of the a–MSH hormone is very brief, as it only lasts for a few minutes. This means that its ability to advance the stimulation of melanocortins – and in turn melanin – is brief and quick.
Melanotan 2’s mechanics make it possible to extend this half-life of the a–MSH hormone. This in turn enables the secretion of melanin to increase, which would then lead to a greater process of melanogenesis and darker skin. According to various clinical tests, it has been determined that Melatonan 2 can promote the kind of stimulation that leads to greater pigmentation without exposure to ultraviolet rays. That said this instance of stimulation does show signs of increase when ultraviolet rays are part of the clinical research process.
Additional clinical studies tied to Melatonan 2 have also found links to other elements of hormonal stimulation, specifically those elements that are related to libido and appetite.
A few of the mechanics that are associated with Melatonan 2 are similarly associated with the peptide Melatonan 1. However, clinical studies have shown that Melatonan 2 has a tendency to stimulate hormone release in a more efficient, faster manner.
The primary focus on clinical research relating to Melatonan 2 has been its ability to theoretically promote less exposure to harmful ultraviolet rays. Specifically, the studies are built around the determination of its role in being an effective measure to reduce the possibility of skin cancer. Even though studies show that hormonal stimulation does increase with ultraviolet rays present, studies also show the stimulation of malanocortins to secrete melanin can happen even without the exposure to ultraviolet rays. This, then, has the potential to decrease the damage that could be caused through ultraviolet exposure, which could include various types of skin cancer. However, it should be noted that studies show that the most dangerous kind of skin cancer – malignant melanoma – is not caused by exposure to ultraviolet rays, as a significant majority of cases involving this type of skin cancer has a lack of an ultraviolet mutation. Instead, this particular form of skin cancer is chiefly caused by indirect DNA damage.
Additionally, clinical research also demonstrates a link between Melanotan 2 and an increase of lipolysis, which is also known as the breaking down of fat. This has led to the theory that the peptide could be related to a boost in weight loss efficiency.
Though Melanotan 2’s potential benefit of guarding from harmful ultraviolet rays is something that has been determined through clinical research, clinical studies have also linked a host of negative side effects to the peptide. Some of these negative side effects include:
Spontaneous effects related to libido
General feeling of lethargy
White skin spots
Appearances of new moles (also known as hyperpigmentation)
Flushing of the face
According to various clinical studies that have conducted comparisons to the side effects of Melanotan 2 and Melanotan 1, the side effects that concern the spontaneous effects of the libido is the one significant difference between the two peptides. The spontaneous libido effects that are associated with Melanotan 2 relate to the clinical findings which suggest that the peptide is linked to the type of hormonal stimulation associated with libido
Other clinical studies have shown that a few of the side effects relating to Melanotan 2 had a tendency to dissipate over the course of a clinical trial. Other side effects, such as flushing of the face and nausea, have lasted through the duration of the clinical trial.
As of now, the effects of Melanotan 2 relating to its overall benefits, side effects, and functionality are still in the phase of clinical testing. Any study that is conducted in relation to its effects and usage should only be done within the parameters of a highly controlled space, such as a scientific research facility or a laboratory. This is particularly noteworthy considering the several potentially negative side effects that have been associated with the peptide through prior clinical study and research.